Workflow
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
ArcellxArcellx(US:ACLX) InvestorPlaceยท2024-01-16 18:51

Industry Overview - Biotech stocks have faced significant challenges over the past two years due to reduced venture capital, shifts in the healthcare landscape post-pandemic, and tighter regulatory environments, but 2024 may signal a recovery for the sector [1] - The FDA approved 50% more novel therapeutics in 2023 compared to 2022, with a total of 55 treatment protocols approved, indicating a potential resurgence in biotech stock performance [1] Regeneron Pharmaceuticals (REGN) - Regeneron Pharmaceuticals has demonstrated consistent stock performance, with a low beta of 0.16, indicating stability even during economic turmoil [2] - The company received FDA approval in August 2023 for a high-dosage variant of its eye disease therapeutic Eylea, enhancing its competitive position against price negotiations from Medicare [2] - Regeneron's flagship drug Dupixent is being tested for chronic obstructive pulmonary disease (COPD), showing a 34% decrease in symptoms, with potential annual sales reaching $20 billion if successful [3] - The company is actively developing compounds in high-interest areas such as monoclonal antibody therapeutics, gene therapy, and gene editing [3] Arcellx Inc (ACLX) - Arcellx is focused on cancer and autoimmune disease treatments, particularly through CAR-T therapeutics, which utilize the patient's immune system to combat cancer [5] - The company has secured significant financial backing from Gilead Sciences, including an $85 million cash payment and a $200 million stock purchase plan, ensuring operational stability through 2027 [6] Beam Therapeutics (BEAM) - Beam Therapeutics is engaged in gene therapy and editing, with a focus on sickle cell treatments, currently in testing stages [7] - The company anticipates significant developments in 2024, supported by a robust cash position of approximately $1.2 billion, allowing for sustained operations through 2027 [8]